The short answer: two different repair philosophies

ChondroFiller is a collagen scaffold placed into a cartilage defect via an ultrasound-guided injection, as an outpatient appointment with no incision and no anaesthetic. Knee surgery — whether microfracture or MACI — requires physical entry into the joint: drilling, tissue harvest, or membrane implantation as a deliberate procedural step.

The underlying difference is one of philosophy rather than ambition. An injectable scaffold approach is additive: material is placed over or within the defect, and the body's own cells are drawn in to begin rebuilding from there. Surgical repair is ablative first: the damaged tissue is cleared or the bone surface is breached to stimulate healing, then new tissue fills the void from the base upward. Neither is inherently superior — the right choice depends on the defect size, the patient's age and activity level, and how much intervention is clinically appropriate.

Both pathways share an important boundary: they are designed for focal cartilage lesions in patients with otherwise stable joint mechanics. Neither is a treatment for advanced, bone-on-bone arthritis — a distinction worth establishing clearly before weighing the options.

How ChondroFiller works once injected

The mechanism starts before any cells arrive. ChondroFiller is a cell-free, acid-extracted Type I collagen liquid — it contains no living cells of its own and requires no laboratory processing or donor tissue. Supplied in a ready-to-use two-chamber syringe, the collagen solution and a neutralising agent are mixed at the point of injection. On contact with the neutral pH environment inside the joint, the liquid undergoes rapid self-polymerisation, hardening into a dimensionally stable hydrogel within approximately three to five minutes.

Think of it as laying a lattice rather than pouring a filler. The scaffold does not repair cartilage directly — it creates a structured framework that the body can build into. Over the weeks and months that follow, the patient's own chondrocytes and marrow-derived cells migrate into the matrix and begin depositing new tissue within its structure. Evidence suggests the body can lay down cartilage-like material through this process, though the extent and quality of that tissue varies between individuals and is not guaranteed.

Critically, nothing in this process involves penetrating the underlying bone. The scaffold sits above the cartilage surface — a key biological distinction from microfracture surgery, which deliberately breaches subchondral bone to bleed stem cells upward into the defect. Because ChondroFiller works by drawing cells into the matrix from the joint environment rather than up from the bone, the subchondral layer remains intact throughout.

Tissue maturation is gradual. Symptom changes and any imaging improvements — such as reductions in bone marrow oedema or alterations in joint-space appearance noted on MRI — typically emerge across a six-to-twenty-four month window, not in the days immediately following treatment.

What surgical cartilage repair actually involves

Surgical routes into a cartilage defect all begin with physical entry into the joint — each then takes a distinct path depending on the size of the lesion and the quality of tissue the surgeon is aiming to restore.

Microfracture is the most widely performed technique for smaller focal defects. Using an awl or drill, the surgeon makes a series of small perforations through the hard subchondral bone plate beneath the damaged cartilage surface. This deliberately triggers bleeding from the bone marrow, allowing a haemorrhagic clot rich in stem cells to form and fill the defect from the base upward. The clot matures into fibrocartilage — a repair tissue that is structurally softer and generally less durable than the native hyaline cartilage it replaces. For some patients this is a clinically useful outcome; for others, the quality gap becomes apparent over time.

MACI (Matrix-Induced Autologous Chondrocyte Implantation) pursues a more ambitious biological result but at greater procedural cost. A first operation harvests a small biopsy of the patient's own cartilage cells; those chondrocytes are then expanded in a laboratory over several weeks. A second surgical procedure implants the cultured cells onto a collagen membrane, which is fixed into the prepared defect. Published evidence suggests MACI can produce hyaline-like cartilage — closer in composition to the original tissue than fibrocartilage — but the pathway involves two anaesthetic episodes and a period of restricted weight-bearing during rehabilitation.

Osteochondral allograft (OCA) transplantation is reserved for larger defects, typically exceeding 2.5 cm², that also involve damage to the underlying bone. Donor cartilage and bone are transplanted as a single plug, restoring full-thickness tissue architecture. This places OCA firmly in a different clinical category from focal-defect injection treatment.

What the published evidence shows

Published data on ChondroFiller are promising but still maturing, and reading them honestly means noting both what they show and where the gaps remain.

The most rigorous recent data come from a 2025 prospective study by Demmer et al., published on PubMed Central, which evaluated ChondroFiller in cartilage defects of the wrist rather than the knee. At follow-up arthroscopy, treated patients showed significantly better cartilage quality than controls — a median Outerbridge score of 1.5 versus 3 (P=0.006) — and post-treatment MRI confirmed reductions in bone marrow oedema. These findings are clinically meaningful, though the joint site limits how directly they translate to knee lesions; the collagen scaffold mechanism is the same, but load profiles and healing environments differ.

For the knee specifically, published observational cohorts suggest that a substantial majority of suitable patients report meaningful pain reduction and functional improvement following ChondroFiller treatment. That figure, however, comes from prospective case series rather than randomised controlled trials, which means it reflects real-world outcomes without the controls needed to isolate the treatment effect confidently.

No head-to-head randomised trial has yet compared ChondroFiller injection directly against microfracture or MACI — that is a genuine evidence gap, and longer-term comparative research is ongoing. What this means practically is that individual outcomes remain variable: the tissue produced may not equal native hyaline cartilage in durability, and realistic expectations matter at the decision stage.

ChondroFiller is CE-marked and available in the UK and across Europe, but it does not currently hold FDA approval, which restricts access for patients based in the United States.

Which patients each approach suits

Deciding between an injectable scaffold pathway and surgical repair is rarely a binary choice made in isolation — it depends on defect size, patient age, activity level, joint mechanics, and individual risk tolerance. The pointers below are orientation, not a clinical assessment.

Patients who may be suited to the outpatient injection pathway tend to share a few characteristics: a focal cartilage defect that sits within the injectable scope (broadly, Grade 2–3 lesions in a mechanically stable joint), a preference for avoiding theatre admission and anaesthetic, or circumstances — medical history, age, occupation — where surgical risk weighs more heavily than usual. The absence of significant malalignment or ligament instability is a prerequisite for either route, so any underlying mechanical issue needs to be assessed and addressed first.

Surgical routes — particularly MACI — are more commonly considered where the defect is larger, where subchondral bone involvement makes a surface-level scaffold insufficient, or in younger high-demand patients where the goal is the most durable possible tissue reconstruction over decades.

Neither pathway is appropriate where osteoarthritis has progressed to advanced bone-on-bone wear; in that context, joint replacement becomes the more relevant clinical conversation.

If the description above matches your situation, a formal suitability assessment is the necessary next step. An assessment via AMSK can help clarify which pathway — injection, surgical referral, or something else — fits your defect profile and broader circumstances.

The practical experience: injection appointment vs. surgical pathway

On the day itself, the two pathways feel markedly different.

A ChondroFiller appointment is an outpatient visit. The target area is located under real-time ultrasound imaging, the injectable collagen matrix is placed in a single session, and patients leave the same day — no hospital admission, no general anaesthetic, no overnight stay. Post-procedure restrictions are typically lighter than those following surgical repair: avoiding significant joint loading while the scaffold stabilises, rather than weeks of enforced non-weight-bearing.

The surgical comparator is a different experience entirely. Theatre admission, anaesthesia, and a structured rehabilitation programme follow any cartilage procedure involving the joint directly. Post-MACI recovery involves a defined non-weight-bearing period measured in weeks, progressive physiotherapy, and a staged return to activity — a significant commitment of time and practical support that is worth factoring into any decision.

Neither route resolves symptoms immediately. The injectable scaffold requires time — published guidance indicates 6–24 months — for the body's own cells to migrate into the matrix and lay down new tissue; surgical pathways carry their own integration timelines. Both also involve structured follow-up, typically MRI and clinical review, to monitor tissue response and catch any issues early.

To find out whether the injection pathway is appropriate for your defect profile and circumstances, an AMSK suitability assessment is the practical next step.